Section 21a-243-7 - Controlled substances in schedule IThe controlled substances listed in this regulation are included by whatever official, common, usual, chemical, or trade name designation in schedule I:
(a) Any of the following opiates, including their isomers, esters, ethers, salts and salts of isomers, esters and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation: (1) Acetylalpha-methylfentanyl;(4) Alphacetylmethadol (except Levo-alphacetylmethadol or LAAM);(7) Alpha-methylfentanyl;(8) Alphamethylthiofentanyl;(11) Beta-hydroxy-fentanyl;(12) Beta-hydroxy-3-methylfentanyl;(23) Dimethylthiambutene;(24) Dioxaphetyl Butyrate;(26) Ethylmethylthiambutene;(33) Levophenacylmorphan;(35) 3-methylthiofentanyl;(41) Para-fluorofentanyl;(42) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);(b) Any of the following opium derivatives, their salts, isomers and salts of isomers, unless specifically excepted whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:(2) Acetyldihydrocodeine;(4) Codeine methylbromide;(10) Etorphine, except hydrochloride salts;(14) Methyldihydromorphine;(15) Morphine methylbromide;(16) Morphine methylsulfonate;(c) Any material, compound, mixture or preparation which contains their salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation: (1) Alpha-ethyltryptamine;(2) 4-bromo-2,5-dimethoxyamphetamine; or 4-bromo-2,5-DMA;(3) 2,5-dimethoxyamphetamine; or 2,5-DMA;(4) 2,5-Dimethoxy-4-ethylamphetamone or DOET;(5) 3,4-M ethylenedioxy-N-ethylamphetamine;(6) 1-methyl-4-phenyl-4-propionoxypiperidine; or MPPP;(7) 3,4-methylenedioxymethamphetamine; or MDMA;(8) 2,5-dimethoxy-4-(n)-propylthiopenenthylamine (2C-T-7);(9) 4-methoxyamphetamine; or PMA;(10) 5-methoxy-3,4-methylenedioxy-amphetamine;(11) 5-Methoxy-nn-Diisopropyltryptamine(5-methoxy-dipt);(12) 4-methyl-2,5-dimethoxyamphetamine; or DOM; or STP(13) 3,4-methylenedioxy amphetamine; or MDA;(14) N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;(15) 3,4,5-trimethoxy amphetamine;(16) benzylpiperazine or BZP;(17) Bufotenine or Mappine;(18) Alphaethyltryptamine;(19) Diethyltryptamine or DET;(20) Dimethyltryptamine or DMT;(22) Lysergic acid diethylamide;(23) MDVP (3,4-methylenedioxypyrovalerone);(24) 3,4-methylenedioxy-N-methycathione (methylone)(25) Mephedrone (4-methylmethcathinone);(27) Parahexyl or Synhexyl;(28) Peyote, meaning all parts of the plants;(29) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine; or PEPAP;(30) N-ethyl-3-piperidyl benzilate;(31) N-methyl-3-piperidyl benzilate;(34) Tetrahydrocannabinols except Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States food and drug administration approved product;(37) Ethylamine analog of phencyclidine, Cyclohexamine or PCE;(38) 4-Bromo-2,5-dimethoxyphenethylamine;(39) Pyrrolidine analog of phencyclidine, PCP or PHP;(41) Thiophene analog of phencyclidine, TPCP or TCP;(42) Tiletamine or 2-(ethylamino)-2-(2-thienyl)-cyclohexanone;(43) Trifluoromethylphenylpiperazine or TFMPP.(d) Any material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, their salts, isomers and salts of isomers unless specifically excepted, wherever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:(1) Gamma-hydroxy butyric acid, except if contained in a drug product for which an application has been approved under section 505 of the Food, Drug and Cosmetic Act;(e) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers: (2) N-benzylpiperazine (some other names: BZP; 1-benzylpiperazine);(8) N,N-Dimethylamphetamine.(f) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of a substance having a psychotropic response primarily by agonist activity at cannabinoid-specific receptors affecting the central nervous system. Specific compounds include, but are not limited to: (1) 1-pentyl-3-(1-naphthoyl)indole (JWH-018);(2) 1-butyl-3-(1-naphthoyl)indole (JWH-073);(3) 1--3-(1-naphthoyl)indole (JWH-200);(4) 5-(1,1-dimethylheptyl)-2--phenol (CP-47,497);(5) 5-(1,1-dimethyloctyl)-2--phenol (cannabi-cyclohexanol CP-47,497 C8 homologue).(g) Any schedule I controlled substance, used for a medical purpose under the supervision of a practitioner, that has been approved by the federal Food and Drug Administration, or successor agency, to have a medical use and is reclassified in any schedule of the controlled substances or unscheduled under the federal Controlled Substances Act shall have the same designation for state purposes as that designated under the federal Controlled Substances Act, unless otherwise specifically designated by the Commissioner of Consumer Protection in accordance with section 21a-243 of the Connecticut General Statutes.Conn. Agencies Regs. § 21a-243-7
Effective July 23, 1987; Amended August 22, 1995; Amended March 6, 2000; Amended June 10, 2003; Amended June 10, 2011; Amended March 29, 2012; Amended September 17, 2013; amended 2/10/2023